N/A N=81 Randomized Double-blind Basic Science

Improving Visual Attention in Schizophrenia

Schizophrenia · Schizoaffective Disorder

Bottom Line

View on ClinicalTrials.gov: NCT03880227 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

Jul 2021

Primary outcome: Primary: Visual Attention to Static Faces — 0.54; 0.52; 0.57; 0.53 proportion of time attending to AOIs

Study Design & Population

Study type: Interventional
Phase: N/A
Interventions: Active anodal tDCS (Device); Sham tDCS (Device)
Age: Adult · 18+ yrs
Sex: All
Sponsor: The University of Texas at Dallas
Primary completion: Mar 2020

Outcome Measures

Outcome	Result	p-value
PRIMARY Visual Attention to Static Faces	0.54; 0.52; 0.57; 0.53	—
PRIMARY Visual Attention to Dynamic Actor	0.47; 0.46; 0.47; 0.47	—
PRIMARY Visual Attention to Dynamic Social Scenes	0.22; 0.23; 0.26; 0.25	—
SECONDARY Fixation Stabilization	0.10; 0.08; 0.05; 0.07	—

Summary

This study investigates whether visual attention can be improved in individuals with schizophrenia by stimulating the brain via transcranial Direct Current Stimulation (tDCS).

Eligibility Criteria

Inclusion Criteria

DSM-IV-TR or DSM-5 diagnosis of schizophrenia or schizoaffective disorder and clinically stable (i.e. no hospitalizations) for at least 8 weeks prior to informed consent and be on a stable medication regimen for at least 6 weeks with no dose changes for a minimum of 2 weeks prior to informed consent.

Exclusion Criteria

The presence or history of a pervasive developmental disorder or mental retardation as defined by a premorbid IQ < 70
Presence or history of medical or neurological disorders in which neural stimulation would be contraindicated (e.g. presence of epilepsy or history of seizures)
Presence of sensory limitations, including visual or hearing impairments that interfere with assessment
History of electroconvulsive therapy
Not proficient in English
Presence of substance abuse in the past one month or dependence not in remission in the past six months

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03880227). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.